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The development of multi-drug combination therapy for
treatment of HIV disease is considered one of the great
success stories of modern medicine. In a period of approx-
imately ten years, the death rate from HIV disease was
reduced by 50 to 80% and changed from a nearly univer-
sally fatal and catastrophic illness to what is now often a
manageable chronic illness. The story of how this was
accomplished, however, is less well known than the out-
come itself, which has been widely heralded in the medi-
cal and public media. The story of this accomplished
though has often been widely distorted in the popular
press and varies considerably from one country to the
next. The media, in its usual quest for simple explana-
tions, suggests that the development of multi-drug combi-
nation therapy was a new and unique discovery that could
largely be attributed to a single research team. The true
story is much more complex and acknowledges the contri-
butions of a wide range of scientists in both academia and
the private pharmaceutical industry. This presentation
traces the historical basis which lead to the development
of the individual therapies and the models of combina-
tion therapy long employed against other diseases. Rather
than being the work of any single group, the development
of HAART is seen to be attributed to a long string of dis-
coveries by multiple groups and individuals beginning in
the 1970s, built upon in the 1980s, and brought to their
ultimate fruition in the 1990s. Major contributions came
from people working in basic science, bio-chemistry, drug
development and clinical testing in dozens of institutions
and companies. It was only through these collective con-
tributions that the success heralded in the mid-1990s
came to be, and it s only through similar, continuing con-
tributions that patients today are benefiting from the
potency, durability and ease of use associated with today's
best regimens. It is a disservice to science, however, to sug-
gest, as the media has done, that any individual or group
was primarily or most responsible for these advances.
Instead, they are the work and accomplishment of the
entire field of HIV medicine.
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